#

Pharmaceutical Companies

: 138
Novo is expanding its portfolio of drugs to better compete with Eli Lilly / Photo: Novo
News·
Novo licensed a Chinese weight-loss pill for $2.6 billion. What makes it unique?
Viking Therapeutics soared last week after the latest data for its GLP-1 therapy / Photo: Facebook/Nasdaq
Small Caps·
Motley Fool analyst calls Viking 'fantastic buy' for risk-tolerant investors
Viking has been developing its own candidate for obesity and type 2 diabetes, VK2735 / Photo: Shutterstock.com / Faizal Ramli
Small Caps·
+1
·
Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot
The maker of Ozempic, Novo, may address the issue of hair loss / Photo: novonordisk.com
News·
The manufacturer of Ozempic is considering entering the hair loss treatment market
Novo disappointed investors who were expecting more concrete plans for turning the business around / Photo: novonordisk.com
News·
Novo's stock plummeted despite sales plans in the billions. What went wrong?
Definium went public in 2025 as MindMed, after which, in January 2026, it changed its name / Photo: X/Definium Therapeutics
Small Caps·
Biotech Definium reports another phase III success for anxiety disorder therapy
Novo Nordisk to Shorten Its Name to Compete with Eli Lilly / Photo: novonordisk.com
News·
Novo Nordisk will shorten its name and change its logo. Will this help revitalize the business?
Shares of Swiss pharmaceutical giant Novartis plummeted 10% during trading on September 8 / Photo: Dmitriy Melnikov / Shutterstock.com
News·
Pharmaceutical giant Novartis is on track for its worst slump in six years following a series of failed trials
A Rothschild analyst deemed the markets reaction to the results of Modernas skin cancer vaccine trials to be excessive / Photo: Shutterstock.com / Panaceum Media
News·
An analyst called Moderna's stock overvalued after it rose 400% since the start of the year
Eli Lilly has once again expanded its portfolio of potential new drugs this year / Photo: Tada Images/Shutterstock.com
News·
Eli Lilly has found a new acquisition target. The company has already spent $20 billion this year
BioNTech and Roche have halted trials of an experimental personalized mRNA immunotherapy for patients with stage II–III colorectal cancer / Photo: Kittyfly / Shutterstock.com
News·
BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?
Moderna will use the proceeds to fund the development of a cancer drug and to pay off debt / Photo: Shutterstock.com / Dmitriy Melnikov
News·
Moderna to Raise $2 Billion Following a Surge in Its Stock Price — Including Funding for a Cancer Vaccine
Load more